| 出品公司: | ZYbscience |
|---|---|
| 载体名称: | pEF1/V5-HisA |
| 质粒类型: | 哺乳细胞表达载体 |
| 高拷贝/低拷贝: | -- |
| 启动子: | EF-1a |
| 克隆方法: | 多克隆位点,限制性内切酶 |
| 载体大小: | 6174bp |
| 5' 测序引物及序列: | T7 Fwd : 5'd[TAATACGACTCACTATAGGG]3' |
| 3' 测序引物及序列: | -- |
| 载体标签: | 6X His, V5 |
| 载体抗性: | Ampicillin |
| 筛选标记: | Neomycin |
| 备注: | -- |
| 产品目录号: | V92020 |
| 稳定性: | 瞬表达 |
| 组成型: | 组成型 |
| 病毒/非病毒: | 非病毒 |
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃低温保存
- 保质期:
三年
- 英文名:
pEF1/V5-HisA
- 库存:
20
- 供应商:
泽叶生物
载体基本信息
载体质粒图谱和多克隆位点信息


载体简介
All pEF or pUB vectors contain a strong promoter for high-level expression in mammalian cells, a choice of selection marker for generating stable cell lines, and an epitope tag for easy detection with a monoclonal antibody and rapid purification on nickel-chelating resin. Each vector is available in three reading frames to simplify cloning in-frame with the fusion tag.
载体序列
LOCUS pEF1/V5 His A 6174 bp DNA SYN
DEFINITION pEF1/V5 His A
ACCESSION
KEYWORDS
SOURCE
ORGANISM other sequences; artificial sequences; vectors.
FEATURES Location/Qualifiers
source 1..6174
/organism="pEF1/V5 His A"
/mol_type="other DNA"
promoter complement(28..56)
/label="AmpR_promoter"
promoter 480..1651
/label="EF1a_promoter"
CDS complement(771..1391)
/label="ORF frame 2"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
misc_feature 1599..1619
/label="EF1a_fwd_primer"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
promoter 1668..1686
/label="T7_promoter"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
misc_feature complement(1896..1913)
/label="BGH_rev_primer"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
terminator 1899..2126
/label="bGH_PA_terminator"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
rep_origin 2189..2495
/label="f1_origin"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
misc_feature complement(2609..2629)
/label="pBABE_3_primer"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
misc_feature complement(2615..2830)
/label="SV40_enhancer"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
promoter 2627..2895
/label="SV40_promoter"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
rep_origin 2794..2871
/label="SV40_origin"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
misc_feature 2856..2875
/label="SV40pro_F_primer"
/translation="MKRRLRTERPFSFVWVTHPPALPSAASSILSSLQQGREAAIFPL
TQLVPTGPALPPRAGRYTAARGQAPEQAGQLETTPVRFSVAALAGPASPNMCAGTHGP
RRRPRPQKPKYQCADLGPHLQDYLARKKASQQVIKNFKWLETYRKQRDRREGATRFAR
GGPSAQARPQLKHEAKGLLKRKASNSPTHFQPEARDQESRTAARWK*"
CDS 3010..3804
/label="ORF frame 1"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
gene 3013..3801
/label="NeoR/KanR"
/gene="NeoR/KanR"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
terminator 3983..4102
/label="SV40_PA_terminator"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
misc_feature 4071..4090
/label="EBV_rev_primer"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
promoter complement(4146..4164)
/label="M13_reverse_primer"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
misc_feature complement(4163..4185)
/label="M13_pUC_rev_primer"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
promoter complement(4199..4228)
/label="lac_promoter"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
gene complement(5300..6160)
/label="Ampicillin"
/gene="Ampicillin"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGR
PVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDL
LSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDE
EHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRY
QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF*"
CDS complement(5300..6160)
/label="ORF frame 3"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验2)、哺乳动物/真核表达载体 pcDNA3.1+ 不含任何标签的真核表达载体 amp/neo 5.4kb E. coli/mammals pcDNA3.1- 不含任何标签的真核表达载体 amp/neo 5.4kb E. coli/mammals pcDNA4/V5-His A, amp 含His标签的真核表达载体 amp/neo pcDNA 3.1(-) myc-hisA 含His标签的真核表达载体 amp/neo pcDNA 3.1(-) myc-hisB 含His标签
基因编辑再次升级!领域大牛刘如谦 Cell 发文开发新工具,可安全高效进行体内基因编辑
4 BE-eVLPs 支持有效、高效的基因编辑,并且显示出最小的脱靶编辑效率和 DNA 整合风险。 图片来源:Cell v4 BE-eVLPs 有效地编辑人类原代细胞和小鼠细胞 为了进一步探索 v4 BE-eVLPs 的效用,他们评估了其在体外靶向和编辑多种原代人类或小鼠细胞的能力。在转导含有纯合子 COL7A1(R185X)突变的原代人类成纤维细胞中,他们观察到高于 95% 的修复效率。这种高效率在小鼠模型的原代成纤维细胞中也得到了重现。 这些结果验证了 v4 BE-eVLPs 的活性并不局限于细胞
750X2+500X2 (DL2000 plus) P10: 3k+2k+1k+800+600 P11: 3k+1k+800+600 P12: 2k+1k+800+600 P13: 2k+1kX2 (专用于2K和1K的制备) P14: 2K P15: 3K P16: 4K P17: 5K P18: 6K P19: 8K P20: 10K II: PCR 扩增制备DNA marker 新技术(有别于上述载体发酵) 基于PCR 技术生产DNA marker 技术的新突破,成本
技术资料暂无技术资料 索取技术资料





